OPCH vs. AMED, CHE, ADUS, AHCO, ENSG, CRSP, CERE, ASND, OGN, and MDGL
Should you be buying Option Care Health stock or one of its competitors? The main competitors of Option Care Health include Amedisys (AMED), Chemed (CHE), Addus HomeCare (ADUS), AdaptHealth (AHCO), The Ensign Group (ENSG), CRISPR Therapeutics (CRSP), Cerevel Therapeutics (CERE), Ascendis Pharma A/S (ASND), Organon & Co. (OGN), and Madrigal Pharmaceuticals (MDGL). These companies are all part of the "medical" sector.
Option Care Health vs.
Option Care Health (NASDAQ:OPCH) and Amedisys (NASDAQ:AMED) are both mid-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, risk, earnings, analyst recommendations, valuation, community ranking, media sentiment, institutional ownership and profitability.
Amedisys has a net margin of 5.02% compared to Option Care Health's net margin of 3.94%. Amedisys' return on equity of 14.35% beat Option Care Health's return on equity.
97.6% of Option Care Health shares are owned by institutional investors. Comparatively, 96.2% of Amedisys shares are owned by institutional investors. 0.4% of Option Care Health shares are owned by company insiders. Comparatively, 2.1% of Amedisys shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
In the previous week, Option Care Health had 4 more articles in the media than Amedisys. MarketBeat recorded 8 mentions for Option Care Health and 4 mentions for Amedisys. Option Care Health's average media sentiment score of 0.79 beat Amedisys' score of 0.54 indicating that Option Care Health is being referred to more favorably in the media.
Amedisys received 411 more outperform votes than Option Care Health when rated by MarketBeat users. Likewise, 57.58% of users gave Amedisys an outperform vote while only 56.94% of users gave Option Care Health an outperform vote.
Option Care Health currently has a consensus target price of $37.88, suggesting a potential upside of 32.62%. Amedisys has a consensus target price of $108.94, suggesting a potential upside of 37.08%. Given Amedisys' higher possible upside, analysts plainly believe Amedisys is more favorable than Option Care Health.
Option Care Health has higher revenue and earnings than Amedisys. Amedisys is trading at a lower price-to-earnings ratio than Option Care Health, indicating that it is currently the more affordable of the two stocks.
Option Care Health has a beta of 1.15, indicating that its share price is 15% more volatile than the S&P 500. Comparatively, Amedisys has a beta of 1.01, indicating that its share price is 1% more volatile than the S&P 500.
Summary
Option Care Health and Amedisys tied by winning 9 of the 18 factors compared between the two stocks.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding OPCH and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip ChartMedia Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart
Option Care Health Competitors List
Related Companies and Tools